Effects of in vivo treatment with diphenyl ditelluride on the phosphorylation of cytoskeletal proteins in cerebral cortex and hippocampus of rats.
In this work, we investigated the effect of a single subcutaneous injection of diphenyl ditelluride (PheTe)(2) in 15-day-old Wistar rats (0.3 micromol/kg body weight) on the phosphorylation of intermediate filament (IF) proteins in cerebral cortex and hippocampus, 1, 3 or 6 days after injection. Results showed that 3 and 6 days after injection with (PheTe)(2), animals presented loss of body weight and cortical hyperphosphorylation of neurofilament subunits, glial fibrillary acidic protein (GFAP) and vimentin (Vim), the neuronal and glial intermediate filaments, respectively. Otherwise, in hippocampus, only GFAP and Vim were hyperphosphorylated and this effect was evidenced 6 days after injection. In cerebral cortex, hyperphosphorylation was accompanied by increased immunocontent of these proteins both in tissue homogenate and in cytoskeletal fraction, while in hippocampus only the immunocontent of cytoskletal-associated GFAP was increased. Moreover, hyperphosphorylation of cortical IF proteins, induced by (PheTe)(2), was totally reversed by a single subcutaneous injection of diphenyl diselenide (PheSe)(2) (5mumol/kg body weight) 24h after (PheTe)(2) administration. Taken together, our results suggest that cortical cytoskeleton is more susceptible to (PheTe)(2) than hippocampal cytoskeleton. Moreover, cytoskeletal dysfunction in cortical and hippocampal cells could be involved in the neurotoxicity induced by acute treatment with (PheTe)(2).
Heimfarth
Luana
L
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2600 anexo, 90035-003 Porto Alegre, RS, Brazil.
Loureiro
Samanta Oliveira
SO
Zamoner
Ariane
A
Pelaez
Priscila de Lima
Pde L
Nogueira
Cristina Wayne
CW
Rocha
João Batista Teixeira da
JB
Pessoa-Pureur
Regina
R
D000704:Analysis of Variance; D000818:Animals; D000831:Animals, Newborn; D001555:Benzene Derivatives / Q000494:pharmacology*; D002540:Cerebral Cortex / Q000187:drug effects*; D003598:Cytoskeletal Proteins / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D006624:Hippocampus / Q000187:drug effects*; D066298:In Vitro Techniques; D009942:Organometallic Compounds / Q000494:pharmacology*; D010766:Phosphorylation / Q000187:drug effects; D011868:Radioisotopes / Q000378:metabolism; D051381:Rats; D013997:Time Factors; D014746:Vimentin / Q000378:metabolism
D001555:Benzene Derivatives; D003598:Cytoskeletal Proteins; D005904:Glial Fibrillary Acidic Protein; D009942:Organometallic Compounds; D011868:Radioisotopes; D014746:Vimentin; C434247:diphenylditelluride